Johnson & Johnson is partnering with Insuline Medical to register and distribute the Israeli company's InsuPad for promoting optimal absorption of insulin in diabetics by warming their injection site.
Johnson & Johnson knew as early as 2001 that its antipsychotic drug Risperdal could cause boys to grow breasts, former FDA chief David Kessler testified in Philadelphia court Wednesday. That's 5 years before the company added a warning about the side effect to the drug's official label.
Bayer and Johnson & Johnson have plunked down hundreds of millions to study the anticoagulant Xarelto for one use after another. Armed with more indications than any of its warfarin-alternative rivals, Xarelto now has the biggest share of that market.
With all the info that's available online these days, the only place that might feel private is behind closed doors in the bathroom. Not so for some staffers at Johnson & Johnson in New York City, where an employee discovered a pinhole camera hidden inside a unisex bathroom.
Johnson & Johnson chairman and CEO Alex Gorsky only highlighted a handful of upcoming medical devices in the company's recent 2014 earnings call. Notably, one of them was the Echelon Flex Powered Vascular Stapler. J&J subsidiary Ethicon is launching the stapler in the U.S. at The Society of Thoracic Surgeons meeting this week in San Diego, CA
Last week opening arguments were made in a case in which Johnson & Johnson is accused of marketing the antipsychotic drug Risperdal for use in young boys and then not sufficiently warning patients that the side effects for some included the possibility they would grow breasts like a woman.
In the latest act of the vaginal mesh litigation drama, plaintiffs' lawyers disputed J&J's claims that fishy phone calls recruiting women to file vaginal mesh-related suits are tainting the legal process and deserve further investigation.
A titanic struggle is nearing its end. Rivals Boston Scientific and Johnson & Johnson are done presenting their arguments in a legal spat involving the disastrous 2005-2006 bidding war and purchase of cardiology player Guidant. The purchase threatens to become an even worse decision for acquirer Boston Scientific, which would owe $7.2 billion if J&J gets its way.
One week after Johnson & Johnson said that women were being illegally solicited by unknown callers to sue over the company's transvaginal mesh devices, J&J has agreed to settle more than 100 product liability lawsuits regarding pelvic mesh products sold by its Mentor subsidiary.
Johnson & Johnson may have been third to bring its Ebola vaccine to human trials, but it is about to pick up the pace on developing its candidate, thanks to a €100 million grant from a European public-private partnership.